adagrasib: Clinical Trials

5 trials of adagrasib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 2 recruiting. 5 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Active not recruiting 3, Recruiting 2
Phase 21Recruiting 1

Follow adagrasib: new trials by email Literature Review of adagrasib trials Research Report on adagrasib

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Adagrasib, Pembrolizumab, Carboplatin - Carcinoma, Non-Small-Cell Lung
Phase 3RecruitingMirati Therapeutics Inc.6302025-04-242026-11-17
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Divarasib, Sotorasib, Adagrasib - Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Phase 3Active not recruitingHoffmann-La Roche3382024-09-232026-09-16
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
MRTX849, Cetuximab, mFOLFOX6 Regimen - Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Phase 3Active not recruitingMirati Therapeutics Inc.4612021-06-242026-09-28
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
MRTX849, Docetaxel - Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Phase 3Active not recruitingMirati Therapeutics Inc.4532021-02-232026-08-11
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Adagrasib, Pembrolizumab - Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2 / Phase 3RecruitingMirati Therapeutics Inc.6262020-12-022026-10-30

Conditions studied

Carcinoma, Non-Small-Cell Lung (4)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Rectal Neoplasms (1)

Sponsors

Mirati Therapeutics Inc. (4)  ·  Hoffmann-La Roche (1)

Countries

Australia (5)  ·  Austria (5)  ·  Belgium (5)  ·  France (5)  ·  Germany (5)  ·  Greece (5)  ·  Hong Kong (5)  ·  Italy (5)  ·  Netherlands (5)  ·  Poland (5)  ·  Portugal (5)  ·  South Korea (5)  ·  Spain (5)  ·  United Kingdom (5)  ·  United States (5)

Results publications

PMID 39752885, PMID 40783289, PMID 42745627

NIH funding

2023 (1)